# A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

> **NCT05005338** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 8 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BIIB122 (DNL151)
- **DRUG:** [14C] BIIB122 ([14C] DNL151)

## Key facts

- **NCT ID:** NCT05005338
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-09-23
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005338, "A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05005338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*